Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Nearly 75% of Americans are classified as overweight or obese. Addressing our nation's health crisis requires much more than ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

Not at all. Novo Nordisk's investigational weight loss therapy, CagriSema, combines semaglutide (the active ingredient in ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Ozempic and Wegovy, made by Novo, are on track to become the world’s top-selling drugs by 2025. Yet in 2024, ‘Wegovy Wednesday’ had already become one of the biggest weight-loss trends to sweep the ...

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.